Articles On Noxopharm (ASX:NOX)

Benchmark ASX index finishes +1% higher ASX Sectors led by Utilities (+4.2%) and all ended higher on the day Funny bunch of small cap winners including MOB, CZR, NGL   The ASX200 doesn’t seem to mind a bit of war on Tuesday, rising very...

This week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other impressive runners including Dimerix, Roots Sustainable Agricultural Technologies and Toys“R”Us.

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

The ASX200 is now at its lowest level in eleven months, closing down .8 of a per cent this afternoon. Across the sectors, it was a sea of red – with only utilities bucking the trend – up nearly .4 of a per cent. Financials dropped 1.5...

It's been another depressing session for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, making it three for three so far this week. After tanking a horrid 1.3% yesterday, the ASX...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Fear continued to grip Wall Street last night, sending all of the United States' major indices backwards. The Dow Jones Industrial Average — an index tracking 30 of the most prominent listed companies in the US — fell 1.29% to 33,003.38 po...

It has been yet another difficult day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1% to 6,871.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why the...

Australian biotechnology company Noxopharm (ASX: NOX) has been granted orphan drug designation (ODD) status by the US Food and Drug Administration for its CRO-67 preclinical drug candidate to treat pancreatic cancer. The FDA grants the stat...

04 Oct 2023 - A snapshot of the stocks on the move, featuring Noxopharm (ASX:NOX), Redstone Resources (ASX:RDS) and Lake Resources (ASX:LKE).

  Noxopharm (ASX:NOX) announces that the US FDA has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. Noxopharm CEO Dr Gisela Mautner said, “our pancreatic...

New Zealand's central bank is likely to maintain its current interest rates ahead of a general election, with all surveyed economists expecting no change at 5.5 percent. However, policymakers may emphasize the potential for future rate hike...

ASX to open lower, as markets fall in New York  US 10-year yields continue to threaten 5%, so everyone’s still upset  Noxopharm comes good on FDA AND… So. Much. Lithium. News.   Aussie shares are headed for another early October retreat...

The US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 preclinical drug candidate for the treatment of pancreatic cancer.

It has been a stunning start to the day for ASX healthcare stock Noxopharm Ltd (ASX: NOX). In morning trade, the biotech company's shares are up 166% to 16.5 cents. Why is this ASX healthcare stock rocketing? Investors have been scrambling...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

ASX200 drops sharply on Wall Street worry Healthcare only sector to rise Small caps led by Noxopharm, Nimy Resources, Alderan and ECS Botanics   The ASX200 has inched below where it was at the start of 2023, while the Australian dollar...

Anatara to progress in Phase 1/2 clinical trial of bowel syndrome Noxopharm to present data at conference for pancreatic cancer   Anatara Lifesciences (ASX:ANR) surged 11% this morning after announcing positive results from Stage 1 of its...

Futures are tipping the ASX to open down this morning, following a mixed session of Wall Street and the impact of oil reaching an 11-month high. Some important news today to keep an eye out for include new retail trade data, job vacancie...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip  The sectors were a shade of spilt claret, with Utilities and Real Estate leading losses Standout small caps: BCAL Diagnostics and American West Metals   Loca...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Noxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its oncology drug Veyonda IONIC is exploring Veyonda’s potential to increase the efficiency of Opdivo, an immune inhibitor used to treat so...

Immutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective against inflammatory skin disease Epsilon Healthcare announced a new CEO   US FDA approves Imugene’s Phase 1 Immuno-oncology biotech Imug...

The ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks could be resolved within the coming days. It comes off the back of President Biden reassuring Americans yesterday the country would “not...

The ASX is set to open higher on Friday after a Wall Street rally overnight FAANG stocks lifted, while Alibaba said it was considering an IPO and a spinoff The US Fed is considering whether it should skip a meeting in June   Aussie shares...

The ASX 200 benchmark has posted a solid slab of gains, up 0.78% for the day Energy and Materials have teamed up to bring the winnings, at +2.5% and +1.6% respectively Creso Pharma’s buy-out of HHI delivers strong backing from investors, u...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Health care stocks have surged in early trade, up more than a per cent. Biotech company Immuron made the most of the boost, with its shares up more than 21 per cent after posting its Q3 FY23 financial figures. Global sales of its trav...

Noxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after saying that ColoSTAT will be presented at a prestigious gathering Immuron surged 24% as global sales rose significantly   Noxopharm (ASX:NOX)...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Noxopharm (NOX) prioritises the development of its two “cutting-edge” preclinical technology platforms moving forward – Chroma and Sofra The company will discontinue its two Veyonda trials, due to protracted timelines, low patient accept...

The ASX is expected to slip on Thursday as eyes are once again on the Reserve Bank. The RBA is expected to deliver its financial stability review in the coming hours, ahead of the Easter long weekend. Here are some ASX-listed companie...

The ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soared ~3.0% because someone missed a memo. Besra Gold is back on top with a 36% leap after Quantum’s cheque cleared customs.   Local markets w...

Noxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence extension to manufacture advanced injectable therapies PharmAust patient in motor neurone disease trial elevated to Cohort 2   Biotech company N...

Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation The company says it has selected a lead candidate for further development, and the product — dubbed SOF-...

Noxopharm (ASX:NOX) has announced the development of a new product candidate based on mRNA technology as part of the company’s Sofra preclinical platform.